Thalidomide-induced bradycardia and its management [7]

Medical Journal of Australia

Volumn 180, Issue 7, 2004, Pages 366-367

  Coutsouvelis, John ^a   Corallo, Carmela E ^a  

^a BOX HILL HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE; MELPHALAN; PAMIDRONIC ACID; ROFECOXIB; SERTRALINE; TAMOXIFEN; THALIDOMIDE;

AGED; ANAMNESIS; BLOOD TOXICITY; BREAST CANCER; CASE REPORT; DIAGNOSTIC PROCEDURE; DROWSINESS; DRUG DOSE REDUCTION; ELECTROCARDIOGRAPHY; FEMALE; HOLTER MONITORING; HUMAN; HYPOTENSION; LETTER; MULTIPLE MYELOMA; OUTCOMES RESEARCH; SEDATION; SIDE EFFECT; SINUS BRADYCARDIA; TREATMENT PLANNING;

EID: 1842779230     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2004.tb05980.x     Document Type: Letter

References (5)

1. Clark TE, Edom N, Larson J, Lindsey U. Thalomid (thalidomide) capsules. A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Safety 2001; 24: 87-117.
2. Kaur A, Yu SS, Lee AJ, Chiao TB. Thalidomide-induced sinus bradycardia. Ann Pharmacother 2003; 37: 1040-1043.
3. Rajkumar SV, Fonseca R, Dispenzieri A, et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 2000; 75: 897-901.
4. Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17: 775-779.
5. Singhal S, Monte J. Thalidomide in cancer. Biomed Pharmacother 2002; 56: 4-12.